To include your compound in the COVID-19 Resource Center, submit it here.

The fork in the road

Access to the next generation of antibody-like assets became more difficult last Friday when GlaxoSmithKline plc unveiled a £230 million ($455 million) bid for Domantis Inc., the developer of domain antibodies (dAbs), the smallest functional binding units of human antibodies. Domantis is still six months away from putting a dAb into patients.

"We were looking to get

Read the full 560 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers